118 related articles for article (PubMed ID: 16023777)
1. Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
Gaszner P; Miklya I
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):5-14. PubMed ID: 16023777
[TBL] [Abstract][Full Text] [Related]
2. The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
Gaszner P; Miklya I
Neuropsychopharmacol Hung; 2004 Dec; 6(4):210-20. PubMed ID: 15825677
[TBL] [Abstract][Full Text] [Related]
3. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.
Shimazu S; Miklya I
Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):421-7. PubMed ID: 15093948
[TBL] [Abstract][Full Text] [Related]
5. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Knoll J; Yoneda F; Knoll B; Ohde H; Miklya I
Br J Pharmacol; 1999 Dec; 128(8):1723-32. PubMed ID: 10588928
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Yoneda F; Moto T; Sakae M; Ohde H; Knoll B; Miklya I; Knoll J
Bioorg Med Chem; 2001 May; 9(5):1197-212. PubMed ID: 11377178
[TBL] [Abstract][Full Text] [Related]
7. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Miklya I
Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
[TBL] [Abstract][Full Text] [Related]
8. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain.
Knoll J; Baghy K; Eckhardt S; Ferdinandy P; Garami M; Harsing LG; Hauser P; Mervai Z; Pocza T; Schaff Z; Schuler D; Miklya I
Life Sci; 2017 Aug; 182():57-64. PubMed ID: 28623006
[TBL] [Abstract][Full Text] [Related]
9. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
[TBL] [Abstract][Full Text] [Related]
10. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.
Knoll J; Miklya I; Knoll B; Yasusa T; Shimazu S; Yoneda F
Life Sci; 2002 Sep; 71(17):1975-84. PubMed ID: 12175892
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, (-)-BPAP.
Knoll J; Miklya I; Knoll B
Life Sci; 2002 Sep; 71(18):2137-44. PubMed ID: 12204771
[TBL] [Abstract][Full Text] [Related]
12. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).
Knoll J; Miklya I
Life Sci; 2016 Dec; 167():32-38. PubMed ID: 27777099
[TBL] [Abstract][Full Text] [Related]
13. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
Knoll J
Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Miklya I; Knoll J
Life Sci; 2003 May; 72(25):2915-21. PubMed ID: 12697274
[TBL] [Abstract][Full Text] [Related]
15. Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes.
Shimazu S; Tanigawa A; Sato N; Yoneda F; Hayashi K; Knoll J
Life Sci; 2003 May; 72(24):2785-92. PubMed ID: 12679194
[TBL] [Abstract][Full Text] [Related]
16. Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.
Knoll J
CNS Drug Rev; 2001; 7(3):317-45. PubMed ID: 11607046
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective function of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, [R-(-)-BPAP], against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells.
Maruyama W; Yi H; Takahashi T; Shimazu S; Ohde H; Yoneda F; Iwasa K; Naoi M
Life Sci; 2004 May; 75(1):107-17. PubMed ID: 15102525
[TBL] [Abstract][Full Text] [Related]
18. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
Miklya I
Neuropsychopharmacol Hung; 2009 Dec; 11(4):217-25. PubMed ID: 20150659
[TBL] [Abstract][Full Text] [Related]
19. Effects of (R)-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in animal models of mood disorders.
Tsunekawa H; Noda Y; Miyazaki M; Yoneda F; Nabeshima T; Wang D
Behav Brain Res; 2008 May; 189(1):107-16. PubMed ID: 18243357
[TBL] [Abstract][Full Text] [Related]
20. [The feasibility of synthetic enhancer substances for preventive nanotherapy].
Miklya I
Neuropsychopharmacol Hung; 2010 Sep; 12(3):395-403. PubMed ID: 20962359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]